Copyright © 1999 by the European Society of Cardiology.
The effect of atropine in vasovagal syncope induced by head-up tilt testing
Heart Disease Department, S. Filippo Neri Hospital, Rome, Italy
Received March 2, 1999; accepted March 5, 1999
Abstract
Aims This single-blinded, randomized, placebo-controlled study was designed and undertaken to assess the efficacy of intravenous atropine administration on haemodynamic impairment induced by head-up tilt testing in patients with vasovagal syncope.
Methods and Results One hundred and thirteen consecutive patients (62 male and 51 female, mean age 46·3 years) with recurrent syncope, no evidence of cardiac, neurological or metabolic disease and a positive head-up tilt test were included in the study. Within 2 weeks of the first head-up tilt test all patients underwent a second tilt test. During this second test, all patients were randomized to receive a bolus of either atropine (0·02mg.kg1) or placebo (isotonic saline solution). The administration of atropine or placebo was performed at the onset of the haemodynamic modifications (heart rate and/or blood pressure fall) in conjunction with typical vasovagal prodromal symptoms. Treatment was taken as effective when symptoms aborted and the test was completed. In 29 of 113 patients the second tilt test was negative and these patients were excluded from final data analysis. Forty-one patients received placebo, which was effective in nine cases (21·9%). Atropine was administered to 43 patients and was effective in 30 cases (69·7%, P<0·01 vs placebo). The effects of treatment were analysed further to consider the haemodynamic patterns of tilt-induced vasovagal reflex. In the cardio-inhibitory form, placebo was never effective (15 cases), while atropine was effective in 15 of 18 cases (83·3%, P<0·001 vs placebo). In the vasodepressor form, placebo was effective in nine of 26 patients (34·6%), while atropine was effective in 15 of 25 cases (60·0%, no significant difference vs placebo).
Conclusions Atropine is fully effective in the cardio-inhibitory form of tilt-induced vasovagal reflex, but is limited in the vasodepressor form.
Key Words: Vasovagal syncope, atropine, head-up tilt testing
f1 Correspondence: Dott. Fabrizio Ammirati, Dipartimento delle Malattie del Cuore, Ospedale S. Filippo Neri, Via Attilio Friggeri, 95, 00136, Roma, Italy.
References
- Kosinski D, Grubb B, Temesey-Armos P. Pathophysiological aspects of neurocardiogenic syncope: current concepts and new perspectives. PACE. 1995;18:716724
- Benditt DG. Neurally mediated syncopal syndromes: pathophysiological concepts and clinical evaluation. PACE. 1997;20:572584
- Fitzpatrick AP, Sutton R. Tilting towards a diagnosis in recurrent unexplained syncope. Lancet. 1989;i:658660
- Grubb BP, Kosinski D. Tilt table testing: concepts and limitations. PACE. 1997;20:781787
- Morillo CA, Leitch JU, Yee R. A placebo controlled trial of intravenous and oral disopyramide for the prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol. 1993;22:18431848[Abstract]
- Kapoor WN, Smith M, Miller NL. Upright tilt testing in evaluating syncope: a comprehensive literature review. Am J Med. 1994;97:7888[CrossRef][ISI][Medline]
- Ammirati F, Colivicchi F, Di Battista G. Electroencephalographic correlates of vasovagal syncope induced by head-up tilt testing. Stroke. 1998;29:23472351
[Abstract/Free Full Text] - Fitzpatrick AP, Ahmed R, Williams S. A randomised trial of medical therapy in malignant vasovagal syndrome or neurally medicated bradycardia/hypotension syndrome. Eur J Cardiac Pacing Electrophysiol. 1991;1:198202
- Brignole M, Menozzi C, Gianfranchi L. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am J Cardiol. 1992;70:339342[CrossRef][ISI][Medline]
- Petersen MEV, Chamberlain-Weber R, Fitzpatrick AP. Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J. 1994;71:274281
[Abstract/Free Full Text] - Petersen MEV, Sutton R. Cardiac pacing for vasovagal syncope: a reasonable therapeutic option. PACE. 1997;20:825826
- Sutton R. Is there an effective pharmacological treatment in the prevention of vasovagal syncope. Arch Mal Coeur. 1996;89:2528
- Raviele A, Brignole M, Menozzi C. Development of an implantable drug delivery system for the treatment of vasovagal syncope: a dream or a real prospect. Raviele A. Cardiac Arrhythmias 1997. Berlin: Springer; 1998. p. 422427
- Benditt DG, Lurie KG. Sensor for the early recognition of imminent vasovagal syncope. Raviele A. Cardiac Arrhythmias 1997. Berlin: Springer; 1998. p. 428434
- Brown JH. Atropine, scopolamine and related antimuscarinic drugs. Goodman Gilman A, Rall TW, Nies AS, Taylor P. The pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press; 1990. p. 150165
- Stueven HA, Tonsefeldt DJ, Thompson BM. Atropine in asystole: human studies. Ann Emerg Med. 1984;13:815821[CrossRef][ISI][Medline]
- Lewis T. Vasovagal syncope and the carotid sinus mechanism with comments on Gower's and Nothnagel's syndrome. BMJ. 1932;1:873876
- Quan KJ, Carison MD, Thames MD. Mechanisms of heart rate and arterial blood pressure control: implications for the pathophysiology of neurocardiogenic syncope. PACE. 1997;20:764774
- Murray RH, Shoropshire S. Effects of atropine on circulatory responses to lower body negative pressure and vasodepressor syncope. Aerospace Med. 1970;41:717740[Medline]
- Goldstein DS, Spanarkel M, Pitterman A. Circulatory control mechanisms in vasodepressor syncope. Am Heart J. 1982;104:10711075[CrossRef][ISI][Medline]
- Fitzpatrick AP, Theodorakis G, Vardas P, Sutton R. Methodology of head-up tilt testing in patients with unexplained syncope. J Am Coll Cardiol. 1991;17:125130[Abstract]
- Van Lieshout JJ, Wieling W, Karemaker JM. Neural circulatory control in vasovagal syncope. PACE. 1997;20:753763
- Benditt DG, Erickson M, Gammage MD. A synopsis: neurocardiogenic syncope, an international symposium, 1996. PACE. 1997;20:851860
- Ammirati F, Colivicchi F, Toscano S. DDD pacing with rate drop response function versus DDI with rate hysteresis pacing for cardioinhibitory vasovagal syncope. PACE. 1998;20:21782181
This article has been cited by other articles:
![]() |
A. Raviele, F. Giada, and G. Gasparini Efficacy of a patient-activated pharmacologic pump using phenylephrine as active drug and prodromal symptoms as a marker of imminent loss of consciousness to abort tilt-induced syncope J. Am. Coll. Cardiol., January 18, 2005; 45(2): 320 - 321. [Full Text] [PDF] |
||||
![]() |
H. Ector Neurocardiogenic, vasovagal syncope Eur. Heart J., December 1, 1999; 20(23): 1686 - 1687. [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

